Baseline anaemia and short dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention

European Journal of Preventive Cardiology 2026

View at publisher
Authors: Francesca Maria Di Muro, Samantha Sartori, D J Angiolillo, Deepak L Bhatt, Davide Cao, Bassem Chehab, George Dangas, Yihan Feng, Jose M de la Torre Hernandez, Mitchell W Krucoff, Vijay Kunadian, Aziz Maksoud
+12 more Nader Mankerious, Angelo Oliva, Héctor Picón, Gert Richardt, Gennaro Sardella, Hölger Thiele, Ralph Toelg, Olivier Varenne, Pascal Vranckx, Stephan Windecker, Marco Valgimigli, Roxana Mehran
DOI: 10.1093/eurjpc/zwag384
Cited by: 1
References: 27

Abstract

AIMS: In patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) has been shown to reduce bleeding without increasing ischemic risk. However, the optimal duration in specific subgroups, particularly anemic patients, remains unclear and was the focus of this analysis. METHODS: This study included 3,364 HBR patients from three prospective trials in the XIENCE Short DAPT Program who underwent PCI with cobalt-chromium everolimus-eluting stents. Anemia was defined as Hb

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research

Publication details

Journal / source
European Journal of Preventive Cardiology
Publisher
Oxford University Press (OUP)
Publication date
21 July 2026
Language
EN